News

These Stocks Are Moving the Most Today: Palantir, Ford, Tesla, Clorox, Hims & Hers, Neurocrine, AMD, and More
Palantir Technologies raises its full-year outlook but the stock falls, while Ford suspends guidance because of uncertainty ...
Fierce Healthcare12h
Hims & Hers' Q1 revenue doubles to $586M, boosted by growth in weight loss business
That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...
24/7 Wall St. on MSN8h
Hims & Hers (HIMS) Blows Out Earnings Expectations
Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...
Hims Reaffirms 2025 Sales Guidance After Posting Quarterly Beat
Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...
Modern Healthcare20h
Hims & Hers names Amazon exec as chief of operations
Novo Nordisk said it would sell its popular weight-loss drug Wegovy on several telehealth platforms, including Hims.
Hims & Hers Appoints Global Operations Expert and Amazon Veteran as Chief Operations Officer
Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Nader ...
Imitation weight-loss drugs boosted Hims & Hers. Executives cashed in.
Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...
24/7 Wall St. on MSN13h
Hims & Hers (NYSE: HIMS) Earnings Are In (Live Coverage)
Hims & Hers Health (NYSE: HIMS) will report its Q1 2025 financial results today, after the market closes with a conference ...